nav-left cat-right
cat-right

Adaptor protein role in diabetes, cancer treatment...

A protein known to be part of a complex communications network within the cell has also been found to be associated with important processes involved in cancer and diabetes. In a study that will be published Feb. 18 in Science Signaling, researchers identified a new role for the adaptor protein p66Shc in controlling glucose metabolism and cell growth, two processes that are highly regulated in our cells. When disruptions in...

Epilepsy drug reverses fatty liver disease

A commonly used epilepsy drug may be able to stop fatty liver disease and prevent Type 2 diabetes in obese people, according to a new study by Johns Hopkins researchers. Scientists found that valproic acid, an anticonvulsant and mood-stabilizing drug prescribed to epilepsy patients, reduced fat accumulation in the liver and lowered blood sugar levels in obese mice. Obesity and a high-fat diet is often associated with the...

Experimental supplement extends lifespan, stops me...

A drug supplement that activates a protein involved in metabolic balance showed an extension in lifespan and improvement in the overall health of mice, according to a new study.The findings, published Feb. 27 in Cell Reports, may eventually help scientists develop therapies to minimize the effects of age-related metabolic and chronic diseases on the human body. Researchers, led by Dr. Rafael de Cabo of the National Institute...

Gene therapy regenerates damaged tissue

An experimental gene therapy developed by investigators at the Icahn School of Medicine at Mount Sinai in New York successfully regenerated heart muscle in pigs following a heart attack. Researchers from VentriNova, a preclinical company spun out of the Icahn School of Medicine, detailed their findings in the Feb. 19 issue of Science Translational Medicine. Treatment with the investigational product, VN-100, also showed signs...

AstraZeneca, Bristol-Myers grant for diabetes rese...

AstraZeneca’s ($AZN) and Bristol-Myers Squibb’s ($BMY) U.S. Diabetes Alliance is giving a three-year, $5 million grant to the American Diabetes Association’s Pathway to Stop Diabetes program. The Pathway initiative provides up to $1.6 million in support for 5 to 7 years to selected investigators to help fund research relevant to any diabetes type, diabetes-related disease state or diabetes...

FDA says new cholesterol drugs may not need outcom...

Members of an experimental class of cholesterol-lowering drugs could get U.S. regulatory approval based on their ability to lower “bad” cholesterol, and may not need to show that they reduce the risk of heart attack and stroke, the Food and Drug Administration said on Thursday. The statement eased industry concerns that the agency would require more onerous “outcome” studies before approving the drugs,...
Page 2 of 212